BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

NCT02569476 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoid Malignancies

Interventions

DRUG: Zanubrutinib
DRUG: Obinutuzumab

Sponsor

BeiGene